Literature DB >> 18050217

It is the best of times; it is the worst of times: is there a way forward? A plethora of treatment options for rheumatoid arthritis, but critical trial design issues.

James R O'Dell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18050217     DOI： 10.1002/art.23140

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  3 in total

1.  Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA.

Authors:  Wilbert B van den Hout
Journal:  Nat Clin Pract Rheumatol       Date:  2008-12-23

2.  Comparative effectiveness of rheumatoid arthritis therapies.

Authors:  Axel Finckh
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

3.  A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years.

Authors:  Paresh Jobanputra; Fiona Maggs; Alison Deeming; David Carruthers; Elizabeth Rankin; Alison C Jordan; Abdul Faizal; Carolyn Goddard; Mark Pugh; Simon J Bowman; Sue Brailsford; Peter Nightingale
Journal:  BMJ Open       Date:  2012-11-12       Impact factor: 2.692
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.